Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | VBC117 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on VBC117, a putative bispecific antibody-drug conjugate (ADC) targeting EGFR and CDH17 (Aug 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| VBC117 | VBC 117|VBC-117 | EGFR Antibody 80 | Limited information is currently available on VBC117, a putative bispecific antibody-drug conjugate (ADC) targeting EGFR and CDH17 (Aug 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07772934 | Phase Ib/II | VBC117 | VBC117First-in-Human Trial of VBC117 in Participants With Advanced Malignant Solid Tumors | Not yet recruiting | AUS | 1 |